October 13, 2022
Life Sciences
  • The Food and Drug Administration (FDA) announced it amended its emergency authorization of the bivalent COVID-19 boosters to include children between the ages of 5 and 11. The FDA’s decision grants Moderna’s request for authorization to administer its bivalent booster to children as young as 6 and grants Pfizer’s request to administer its own booster to children as young as 5. (Articles here, here, here, here, here, and here)